What is Biosyntia?
Biosyntia is an industrial biotech innovator specializing in the development of high-efficiency bio-based manufacturing processes. At the core of its operations is the proprietary Biosynthetic Selections technology, which enables the rapid engineering of microbes and fermentation pathways. This platform significantly reduces the time, cost, and technical risk associated with scaling biological production. Founded by a team of experts including Hans Genee, Andreas Lausten, and Professor Morten Sommer, the company has garnered international acclaim for its contributions to sustainable industrial practices. By optimizing strain performance, Biosyntia provides a scalable framework for producing essential ingredients and materials, effectively bridging the gap between laboratory-scale innovation and commercial-scale industrial output.
How much funding has Biosyntia raised?
Biosyntia has raised a total of $13.6M across 2 funding rounds:
Angel/Seed
$1.9M
Other Financing Round
$11.7M
Angel/Seed (2015): $1.9M with participation from Novo A/S
Other Financing Round (2022): $11.7M led by Novo Seeds, European Circular Bioeconomy Fund, and Sofinnova Partners
Key Investors in Biosyntia
Novo A/S
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term value creation in life sciences.
European Circular Bioeconomy Fund
ECBF is a specialist venture capital firm focused on the regenerative economy, investing in pioneering companies that aim to align economic growth with environmental sustainability.
Novo Seeds
Novo Seeds is an investment entity operating within the life sciences and agricultural technology sectors, providing critical early-stage and growth capital.
What's next for Biosyntia?
With the recent influx of capital, Biosyntia is well-positioned to accelerate the commercialization of its pipeline and expand its manufacturing footprint. The strategic focus will likely center on scaling its fermentation infrastructure to meet the growing demand for sustainable, bio-derived products across global markets. As the company moves into this next phase of enterprise-level growth, it will continue to refine its Biosynthetic Selections platform to enhance yield and cost-competitiveness. The ongoing support from specialized venture capital firms suggests a long-term commitment to establishing Biosyntia as a cornerstone of the circular bioeconomy, where economic performance and environmental stewardship are intrinsically linked.
See full Biosyntia company page
